

Immune Globulin (IVIG and SCIG)

Policy Number: CS2025D0035TT
Effective Date: April 1, 2025

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	11
Background	15
Clinical Evidence	15
U.S. Food and Drug Administration	24
References	24
Policy History/Revision Information	29
Instructions for Use	31

Commercial Policy
• Immune Globulin (IVIG and SCIG)

Application

This Medical Benefit Drug Policy does not apply to the states listed below; refer to the state-specific policy/guideline, if noted:

State	Policy/Guideline
Arizona	Refer to the state’s Medicaid clinical policy. Use drug specific criteria if available for the specific product, otherwise this medical benefit drug policy applies
Florida	Refer to the state’s Medicaid clinical policy. Use drug specific criteria if available for the specific product, otherwise this medical benefit drug policy applies
Indiana	Immune Globulin (IVIG and SCIG) (for Indiana Only)
Kansas	Refer to the state’s Medicaid clinical policy
Louisiana	Refer to the state’s Medicaid clinical policy
North Carolina	None
Ohio	Immune Globulin (IVIG and SCIG) (for Ohio Only)
Pennsylvania	Immune Globulin (IVIG and SCIG) (for Pennsylvania Only)

Coverage Rationale

This policy refers to FDA-approved intravenous (IV) and subcutaneous (SC) immune globulin (IG) products including, but not limited to, the following (list not all inclusive):

- Alyglo™ (IV)
- Asceniv™ (IV)
- Bivigam® (IV)
- Cutaquig® (SC)
- Cuvitru® (SC)
- Flebogamma® DIF (IV)
- Gammagard® Liquid (IV, SC)
- Gammagard® S/D (IV)
- Gammaked™ (IV, SC)
- Gammaplex® (IV)
- Gamunex®-C (IV, SC)
- Hizentra® (SC)
- HyQvia® (SC)
- Octagam® (IV)
- Panzyga® (IV)
- Privigen® (IV)
- Xembify® (SC)

The intravenous (IVIG) and subcutaneous immune globulin (SCIG) Preferred Product Criteria in this section applies to the following states: CO, FL, HI, KY, MD, MI, MN, MS, NE, NJ, NY, RI, TN, VA, and WA. For all other states, coverage will be provided contingent on the coverage criteria in the [Diagnosis-Specific Criteria](#) section.

Coverage for SCIG products: Cuvitru[®], Hizentra[®], HyQvia[®], and Xembify[®] is contingent on criteria in the [Diagnosis-Specific Criteria](#) section.

Coverage for IVIG products, except for Alyglo[™], Asceniv[™], and Panzyga[®] is contingent on criteria in the [Diagnosis-Specific Criteria](#) section.

Subcutaneous Immune Globulin Preferred Product Criteria

Cutaquig[®] is a non-preferred SCIG product. Coverage for Cutaquig[®] is contingent on the Preferred Product Criteria and [Diagnosis-Specific Criteria](#).

Treatment with Cutaquig[®] is medically necessary for the indications specified in this policy when one of the criteria below are met:

- **Both** of the following:
 - History of a trial of adequate dose and duration of at least **one** of the following preferred SCIG products, resulting in minimal clinical response (provider must submit information regarding drug, dose, and duration of therapy):
 - § Cuvitru[®]; **or**
 - § Hizentra[®]; **or**
 - § HyQvia[®]; **or**
 - § Xembify[®]
 - and**
 - Physician attests that, in their clinical opinion, the clinical response with Cutaquig[®] would be expected to be superior than experienced with the preferred SCIG products
- or**
- **Both** of the following:
 - History of contraindication, intolerance, or severe adverse event to **all** preferred SCIG products not previously tried (provider must submit information regarding drug, dose, and duration of therapy):
 - § Cuvitru[®]; **and**
 - § Hizentra[®]; **and**
 - § HyQvia[®]; **and**
 - § Xembify[®]
 - and**
 - Physician attests that, in their clinical opinion, the same contraindication, intolerance, or severe adverse event would not be expected to occur with Cutaquig[®]

Intravenous Immune Globulin Preferred Product Criteria

Alyglo[™], Asceniv[™], and Panzyga[®] are non-preferred IVIG products. Coverage for Alyglo[™], Asceniv[™], and Panzyga[®] is contingent on Preferred Product Criteria and [Diagnosis-Specific Criteria](#).

Treatment with Alyglo[™], Asceniv[™], or Panzyga[®] is medically necessary for the indications specified in this policy when one of the criteria below are met:

- **Both** of the following:
 - History of a trial of adequate dose and duration of at least **two** other IVIG products, resulting in minimal clinical response. Alternative IVIG options are, but not limited to Bivigam[®], Gammagard[®], Gamunex[®], Privigen[®], etc. (provider must submit information regarding drug, dose, and duration of therapy); **and**
 - Physician attests that, in their clinical opinion, the clinical response with Alyglo[™], Asceniv[™], or Panzyga[®] would be expected to be superior than experienced with other IVIG products
- or**
- **Both** of the following:
 - History of contraindication, intolerance, or severe adverse event to **all** other IVIG products not previously tried. Alternative IVIG options are, but not limited to: Bivigam[®], Gammagard[®], Gamunex[®], Privigen[®], etc. (provider must submit information regarding drug, dose, and duration of therapy); **and**
 - Physician attests that, in their clinical opinion, the same contraindication, intolerance, or severe adverse event would not be expected to occur with Alyglo[™], Asceniv[™], or Panzyga[®]

Diagnosis-Specific Criteria

In absence of a product listed, and in addition to applicable criteria outlined within the drug policy, prescribing and dosing information from the package insert is the clinical information used to determine benefit coverage.

- [Acute disseminated encephalomyelitis](#)
- [Autoimmune bullous diseases](#)
- [Bone marrow transplantation \(BMT\)](#)
- [Chronic inflammatory demyelinating polyneuropathy](#)
- [Chronic lymphocytic leukemia \(CLL\), prevention of infection in B-cell CLL](#)
- [Cytomegalovirus \(CMV\) induced pneumonitis in solid organ transplants](#)
- [Dermatomyositis or polymyositis](#)
- [Encephalitis, immune checkpoint inhibitor-induced, severe or progressive](#)
- [Feto-neonatal alloimmune thrombocytopenia](#)
- [Guillain-Barré syndrome \(GBS\)](#)
- [HIV-infection, prevention of bacterial infection in pediatric HIV](#)
- [IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathy](#)
- [Immune thrombocytopenia](#)
- [Kawasaki disease](#)
- [Lambert-Eaton myasthenic syndrome \(LEMS\)](#)
- [Lennox Gastaut syndrome](#)
- [Lymphoproliferative disease, treatment of bacterial infections](#)
- [Multifocal motor neuropathy \(MMN\)](#)
- [Multiple myeloma, prevention of infection](#)
- [Multiple sclerosis, relapsing forms](#)
- [Myasthenia gravis](#)
- [Neuromyelitis optica](#)
- [Paraproteinemic neuropathy](#)
- [Parvovirus B19 infection, treatment, immunocompromised host \(solid organ transplant recipient or HIV-related\)](#)
- [Post B-cell targeted therapies](#)
- [Posttransfusion purpura](#)
- [Primary immunodeficiency syndromes](#)
- [Rasmussen syndrome](#)
- [Solid organ transplantation, desensitization, prevention, or treatment of acute humoral rejection](#)
- [Staphylococcal toxic shock](#)
- [Stiff-person syndrome](#)
- [Thrombocytopenia, secondary to HCV, HIV, or pregnancy](#)
- [Toxic epidermal necrolysis or Stevens-Johnson syndrome](#)
- [Warm autoimmune hemolytic anemia](#)
- [Unproven uses](#)

The Following Information Pertains to Medical Necessity Review

General Requirements (Applicable to All Medical Necessity Requests)

- For **initial therapy**, all of the following:
 - Diagnosis; **and**
 - Medical records documenting **both** of the following:
 - § History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable; **and**
 - § Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested **and**
 - **One** of the following:
 - § Prescriber attests dosing is in accordance with the United States Food and Drug Administration (FDA) approved labeling; **or**
 - § For indications without FDA approved dosing, prescriber attests there is published clinical evidence to support the dosing
- and**
- Initial authorization will be for no more than 12 months
- For **continuation of therapy**, all of the following:
 - Documentation of positive clinical response to immune globulin therapy; **and**
 - **One** of the following:
 - § Prescriber attests dosing is in accordance with the United States Food and Drug Administration (FDA) approved labeling; **or**
 - § For indications without FDA approved dosing, prescriber attests there is published clinical evidence to support the dosing
- and**
- Authorization will be for no more than 12 months

Diagnosis-Specific Requirements

The information below indicates additional requirements for those indications having specific medical necessity criteria in the list of proven indications.

Immune globulin is proven for:

Dermatology

- **Autoimmune bullous diseases** [pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, epidermolysis bullosa acquisita, pemphigoid gestationis, linear IgA bullous dermatosis]
Immune globulin is medically necessary for the treatment of autoimmune bullous diseases when all of the following criteria are met:
 - Diagnosis of an autoimmune bullous disease; **and**
 - Extensive and debilitating disease; **and**
 - History of failure, contraindication, or intolerance to systemic corticosteroids with concurrent immunosuppressive treatment (e.g., azathioprine, cyclophosphamide, mycophenolate mofetil)
- **Toxic epidermal necrolysis or Stevens-Johnson syndrome**

Hematology

- **Feto-neonatal alloimmune thrombocytopenia (AIT)**
Immune globulin is medically necessary for the treatment of feto-neonatal alloimmune thrombocytopenia when all of the following criteria are met:
 - **For pregnant women:**
 - § Diagnosis of feto-neonatal alloimmune thrombocytopenia (AIT); **and**
 - § **One** or more of the following:
 - Previously affected pregnancy; **or**
 - Family history of the disease; **or**
 - Platelet alloantibodies found on screening
 - **For newborns:**
 - § Diagnosis of feto-neonatal alloimmune thrombocytopenia; **and**
 - § Thrombocytopenia that persists after transfusion of antigen-negative compatible platelets
- **Immune thrombocytopenia [idiopathic thrombocytopenic purpura (ITP)]**
Immune globulin is medically necessary for the treatment of idiopathic thrombocytopenic purpura when at least one of the following criteria is met:
 - **Both** of the following:
 - § Diagnosis of acute thrombocytopenic purpura (ITP); **and**
 - § Documented platelet count $< 50 \times 10^9 / L$ (obtained within the past 30 days)**or**
 - **Both** of the following:
 - § Diagnosis of chronic thrombocytopenic purpura (ITP); **and**
 - § History of failure, contraindication, or intolerance to at least **one** of the following:
 - Corticosteroids; **or**
 - Splenectomy
- **Posttransfusion purpura**
Immune globulin is medically necessary for the treatment of posttransfusion purpura when both of the following criteria are met:
 - Diagnosis of posttransfusion purpura; **and**
 - IVIG dose does not exceed 2 days
- **Thrombocytopenia, secondary to hepatitis C virus (HCV), human immunodeficiency virus (HIV), or pregnancy**
Immune globulin is medically necessary for the treatment of thrombocytopenia when one of the following criteria is met:
 - For **initial therapy**, **all** of the following:
 - § **One** of the following:
 - **Both** of the following:
 - Diagnosis of thrombocytopenia secondary to HCV infection; **and**
 - Patient is receiving concurrent antiviral therapy, unless contraindicated
 - or**
 - **Both** of the following:
 - Diagnosis of thrombocytopenia secondary HIV infection; **and**
 - Patient is receiving concurrent antiviral therapy, unless contraindicated
 - or**
 - Diagnosis of thrombocytopenia secondary to pregnancy

and

§ Documented platelet count < 50 x 10⁹ / L (obtained within the past 30 days)

- **Warm autoimmune hemolytic anemia**

Immune globulin is medically necessary for the treatment of warm autoimmune hemolytic anemia when all of the following criteria are met:

- Diagnosis of warm autoimmune hemolytic anemia; **and**
 - Other types of autoimmune hemolytic anemia have been ruled out; **and**
 - History of failure, contraindication, or intolerance to glucocorticoids (e.g., prednisone, methylprednisolone); **and**
 - History of failure, contraindication, or intolerance to at least **one** of the following:
 - § Rituximab; **or**
 - § Immunosuppressive agent [e.g., azathioprine, cyclophosphamide, cyclosporin A, danazol, mycophenolate mofetil (MMF), sirolimus, Tavalisse (fostamatinib)]
- and**
- Patient is still transfusion-dependent at a minimum of two weeks after initiation of rituximab or a second-line immunosuppressive agent; **and**
 - Immune globulin will be used as an adjunct to other therapies

Infectious Disease

- **Chronic lymphocytic leukemia (CLL), prevention of infection in B-cell CLL**

Immune globulin is medically necessary for the prevention of infection in B-cell chronic lymphocytic leukemia when all of the following criteria are met:

- Diagnosis of B-cell chronic lymphocytic leukemia (CLL); **and**
- **One** of the following:
 - § Documented hypogammaglobulinemia (IgG < 500 mg/dL); **or**
 - § History of bacterial infection(s) associated with B-cell CLL

- **Cytomegalovirus (CMV)-induced pneumonitis in solid organ transplants**

- **HIV-infection, prevention of bacterial infection in pediatric HIV**

Immune globulin is medically necessary for the prevention of bacterial infection in pediatric HIV when all of the following criteria are met:

- Diagnosis of HIV disease; **and**
- Patient age ≤ 13 years; **and**
- **One** of the following criteria:
 - § Documented hypogammaglobulinemia (IgG < 400 mg/dL); **or**
 - § Functional antibody deficiency as demonstrated by either poor specific antibody titers or recurrent bacterial infections

- **Lymphoproliferative disease, treatment of bacterial infections**

- **Multiple myeloma, prevention of infection in multiple myeloma**

Immune globulin is medically necessary for the prevention of infection in multiple myeloma when all of the following criteria are met:

- Diagnosis of multiple myeloma; **and**
- **One** of the following:
 - § Documented hypogammaglobulinemia (IgG < 500 mg/dL); **or**
 - § History of bacterial infection(s) associated with multiple myeloma

- **Parvovirus B19 infection, treatment, immunocompromised host (Solid organ transplant recipient or HIV-related)**

- **Post B-cell targeted therapies**

Immune globulin is medically necessary for the prevention of infection secondary to B-cell targeted therapy when all of the following criteria are met:

- Documentation confirming previous treatment of B-cell targeted therapy within the last 100 days [e.g., CAR-T (e.g., Kymriah), Rituxan (rituximab), Besponsa (inotuzumab ozogamicin)]; **and**
- **Both** of the following:
 - § Documented hypogammaglobulinemia (IgG < 500 mg/dL); **and**

§ History of bacterial infection(s) associated with B-cell depletion

- **Staphylococcal toxic shock**

Neurology

- **Acute disseminated encephalomyelitis (ADEM)**
Immune globulin is medically necessary for the treatment of acute disseminated encephalomyelitis (ADEM) when both of the following criteria are met:
 - Diagnosis of acute disseminated encephalomyelitis (ADEM); **and**
 - History of failure, contraindication, or intolerance to intravenous glucocorticoids
- **Chronic inflammatory demyelinating polyneuropathy**
Immune globulin is medically necessary for the treatment of chronic inflammatory demyelinating polyneuropathy when all of the following criteria are met:
 - **Initial Therapy:**
 - § Diagnosis of chronic inflammatory demyelinating polyneuropathy as confirmed by **all** of the following:
 - Progressive symptoms present for at least 2 months; **and**
 - Symptomatic polyradiculoneuropathy as indicated by progressive or relapsing motor or sensory impairment of more than one limb; **and**
 - Electrodiagnostic findings (consistent with [EFNS/PNS guidelines](#) for definite CIDP) indicating at least **one** of the following criteria are present:⁶⁶
 - Motor distal latency prolongation in 2 nerves; **or**
 - Reduction of motor conduction velocity in 2 nerves; **or**
 - Prolongation of F-wave latency in 2 nerves; **or**
 - Absence of F-waves in at least 1 nerve; **or**
 - Partial motor conduction block of at least 1 motor nerve; **or**
 - Abnormal temporal dispersion in at least 2 nerves; **or**
 - Distal CMAP duration increase in at least 1 nerve
 - and**
 - § Prescribed by or in consultation with a neurologist
 - **Continuation of Therapy:**
 - § Documentation of positive clinical response to therapy as measured by an objective scale [e.g., Rankin, Modified Rankin, Medical Research Council (MRC) scale]
- **Encephalitis, immune checkpoint inhibitor-induced, severe, or progressive**
Immune globulin is medically necessary for the treatment of encephalitis, immune checkpoint inhibitor-induced, severe, or progressive, when all of the following criteria are met:
 - Diagnosis of encephalitis, immune checkpoint inhibitor-induced, severe, or progressive; **and**
 - History of failure, contraindication, or intolerance to glucocorticoids (e.g., methylprednisolone); **and**
 - The use of the immune checkpoint inhibitor has been interrupted; **and**
 - Prescribed by or in consultation with a neurologist
- **Guillain-Barré syndrome (GBS)**
Immune globulin is medically necessary for the treatment of Guillain-Barré syndrome when all of the following criteria are met:
 - Diagnosis of Guillain-Barré syndrome; **and**
 - Severe disease requiring aid to walk; **and**
 - Onset of neuropathic symptoms within the last four weeks; **and**
 - Prescribed by or in consultation with a neurologist
- **IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathy^{7,58}**
- **Lambert-Eaton myasthenic syndrome (LEMS)**
Immune globulin is medically necessary for the treatment of Lambert-Eaton myasthenic syndrome when all of the following criteria are met:
 - Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS); **and**
 - History of failure, contraindication, or intolerance to immunomodulator monotherapy (e.g., azathioprine, corticosteroids); **and**

- Concomitant immunomodulator therapy (e.g., azathioprine, corticosteroids), unless contraindicated, will be used for long-term management of LEMS; **and**
- Prescribed by or in consultation with a neurologist

- **Lennox Gastaut syndrome**

Immune globulin is medically necessary for the treatment of Lennox Gastaut syndrome when all of the following criteria are met:

- History of failure, contraindication, or intolerance to initial treatment with traditional anti-epileptic pharmacotherapy (e.g., lamotrigine, phenytoin, valproic acid); **and**
- Prescribed by or in consultation with a neurologist

- **Multifocal motor neuropathy (MMN)**

Immune globulin is medically necessary for the treatment of multifocal motor neuropathy when both of the following criteria are met:

- **Initial Therapy:**
 - § Diagnosis of multifocal motor neuropathy as confirmed by **all** of the following:
 - Weakness with slowly progressive or stepwise progressive course over at least one month; **and**
 - Asymmetric involvement of **two** or more nerves; **and**
 - Absence of motor neuron signs and bulbar signs
 - and**
 - § Prescribed by or in consultation with a neurologist
- **Continuation of Therapy:**
 - § Documentation of positive clinical response to therapy as measured by an objective scale [e.g., Rankin, Modified Rankin, Medical Research Council (MRC) scale]

- **Multiple sclerosis, relapsing forms**

(Note: Treatment of any other type of multiple sclerosis with immune globulin is not supported by clinical evidence)

Immune globulin is medically necessary for the treatment of relapsing forms of multiple sclerosis when all of the following criteria are met:

- **Initial Therapy:**
 - § Diagnosis of relapsing forms of multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses); **and**
 - § Documentation of an MS exacerbation or progression (worsening) of the patient's clinical status from the visit prior to the one prompting the decision to initiate immune globulin therapy; **and**
 - § History of failure, contraindication, or intolerance to at least **two** of the following agents:
 - Interferon β -1a (Avonex[®] or Rebif[®])
 - Interferon β -1b (Betaseron[®] or Extavia[®])
 - Glatiramer acetate (Copaxone[®] or Glatopa[®])
 - Dimethyl fumarate (Tecfidera[®])
 - Teriflunomide (Aubagio[®])
 - Fingolimod (Gilenya[®])
 - Peginterferon beta-1a (Plegridy[™])
 - Natalizumab (Tysabri[®])
 - Natalizumab-sztn (Tyruko[®])
 - Ocrelizumab (Ocrevus[®])
 - Rituximab (Riabni[®], Rituxan[®], Ruxience[®], and Truxima[®])
 - Siponimod (Mayzent[®])
 - Ozanimod (Zeposia[®])
 - Ofatumumab (Kesimpta[®])
 - Monomethyl fumarate (Bafiertam)
 - Cladribine (Mavenclad)
 - Ublituximab (Briumvi[®])
 - and**
 - § Prescribed by or in consultation with a neurologist

- **Myasthenia gravis**

(Note: Evidence does not support the use of immune globulin maintenance therapy for ocular myasthenia)

- **Myasthenia Gravis exacerbation:**

Immune globulin is medically necessary for the treatment of myasthenic exacerbation when all of the following criteria are met:

- § Diagnosis of generalized myasthenia gravis; **and**
- § Evidence of myasthenic exacerbation, defined by at least **one** of the following symptoms in the last month:
 - Difficulty swallowing; **or**
 - Acute respiratory failure; **or**
 - Major functional disability responsible for the discontinuation of physical activity; **or**
 - Recent immunotherapy treatment with a checkpoint inhibitor [e.g., Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab)]

and

- § **One** of the following:
 - History of failure, contraindication, or intolerance to immunomodulator therapy (e.g., azathioprine, mycophenolate mofetil, cyclosporine) for long-term management of myasthenia gravis; **or**
 - Currently receiving immunomodulator therapy (e.g., azathioprine, mycophenolate mofetil, cyclosporine) for long-term management of myasthenia gravis

and

- § Prescribed by or in consultation with a neurologist

- **Myasthenia gravis, refractory:**

Immune globulin is medically necessary for the treatment of refractory myasthenia gravis when all of the following criteria are met:

- § Diagnosis of refractory generalized myasthenia gravis by or in consultation with a physician or center with expertise in management of myasthenia gravis; **and**
- § Documentation that the disease status is unchanged or worsening (persistent or worsening symptoms that limit functioning) despite failure, contraindication, or intolerance to **both** of the following (used in adequate doses and duration):
 - Corticosteroids; **and**
 - **Two** immunomodulator therapies (e.g., azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, tacrolimus)

and

- § Currently receiving immunomodulator therapy (e.g., corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, tacrolimus), used in adequate doses, for long-term management of myasthenia gravis; **and**
- § Prescribed by or in consultation with a neurologist

- **Neuromyelitis optica**

Immune globulin is medically necessary for the treatment of neuromyelitis optica when all of the following criteria are met:

- **Initial Therapy:**

- § Diagnosis of neuromyelitis optica spectrum disorder (NMOSD) by a neurologist confirming **all** of the following:
 - Serologic testing for anti-aquaporin-4 immunoglobulin G (AQP4-IgG)/NMO-IgG antibodies has been performed; **and**
 - Past medical history of (if AQP4-IgG/NMO-IgG positive **one** of the following, if negative **two** of the following):
 - Optic neuritis
 - Acute myelitis
 - Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
 - Acute brainstem syndrome
 - Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
 - Symptomatic cerebral syndrome with NMOSD-typical brain lesions
 - Diagnosis of multiple sclerosis or other diagnoses have been ruled out

and

- § History of failure, contraindication, or intolerance to at least **three** of the following:
 - Azathioprine
 - Corticosteroids
 - Mycophenolate mofetil
 - Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab)]
 - Anti-IL6 therapy [e.g., Actemra (tocilizumab), Enspryng (satralizumab-mwge)]
 - Anti-CD19 therapy [e.g., Uplizna (inebilizumab-cdon)]
 - Anti-CD20 therapy (e.g., rituximab)

and

- § Patient is not receiving immune globulin in combination with any of the following:

- Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]; **or**
- Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab)]; **or**
- Anti-IL6 therapy [e.g., Actemra (tocilizumab), Enspryng (satralizumab-mwge)]; **or**
- Anti-CD19 therapy [e.g., Uplizna (inebilizumab-cdon)]; **or**
- Anti-CD20 therapy (e.g., rituximab)

and

§ Prescribed by or in consultation with a neurologist

- **Paraproteinemic neuropathy**

- **Rasmussen syndrome**

Immune globulin is medically necessary for the treatment of Rasmussen syndrome when the following criteria are met:

- Documentation of **one** of the following demonstrating that:
 - § Short term amelioration of encephalitis is needed prior to definitive surgical therapy; **or**
 - § Disease symptoms (e.g., seizures) persist despite surgical treatment; **or**
 - § The patient is not a candidate for surgical treatment

- **Stiff-person syndrome**

Immune globulin is medically necessary for the treatment of stiff-person syndrome when all of the following criteria are met:

- **Initial Therapy:**
 - § Diagnosis of stiff-person syndrome; **and**
 - § History of failure, contraindication, or intolerance to GABAergic medication (e.g., baclofen, benzodiazepines); **and**
 - § Prescribed by or in consultation with a neurologist

Primary Immunodeficiency

- **Primary immunodeficiency syndromes** ([refer to the disease list below](#))

Immune globulin is medically necessary for the treatment of primary immunodeficiency syndromes when both of the following criteria are met:

- Diagnosis of primary immunodeficiency; **and**
- Clinically significant functional deficiency of humoral immunity as evidenced by **one** of the following:
 - § Documented failure to produce antibodies to specific antigens; **or**
 - § History of significant recurrent infections

Rheumatology

- **Dermatomyositis or polymyositis**

Immune globulin is medically necessary for the treatment of dermatomyositis or polymyositis when all of the following criteria are met:

- Diagnosis of dermatomyositis or polymyositis; **and**
- History of failure, contraindication, or intolerance to immunosuppressive therapy (e.g., azathioprine, corticosteroids, cyclophosphamide, methotrexate)

- **Kawasaki disease**

Immune globulin is medically necessary for the treatment of Kawasaki disease when both of the following criteria are met:

- Diagnosis of Kawasaki disease; **and**
- IVIG treatment does not exceed five consecutive days

Transplantation

- **Bone marrow transplantation (BMT)**

Immune globulin is medically necessary after allogeneic BMT when all of the following criteria are met:

- **One** of the following uses:
 - § Prevention of acute graft vs. host disease (GVHD); **or**
 - § Prevention of infection
- and**
- Confirmed allogeneic bone marrow transplant within the last 100 days; **and**

- Documented severe hypogammaglobulinemia (IgG < 400 mg/dL)
- **Solid organ transplantation, desensitization, prevention, or treatment of acute antibody-mediated rejection (i.e., B-cell mediated or humoral rejection)**

Immune globulin is unproven and not medically necessary for:

- Acquired hemophilia
- Adrenoleukodystrophy
- Alzheimer's disease
- Amyotrophic lateral sclerosis (ALS)
- Antiphospholipid antibody syndrome (APS) in pregnancy
- Asthma
- Atopic dermatitis
- Autism spectrum disorders
- Autoimmune liver disease
- Autoimmune neutropenia
- Bone marrow transplantation (BMT), prevention of acute graft vs. host disease (GVHD) after autologous BMT
- Bone marrow transplantation (BMT), prevention of chronic graft vs. host disease (GVHD) after autologous BMT
- Bone marrow transplantation (BMT), prevention of infection after autologous BMT
- Campylobacter species-induced enteritis
- Cerebral infarctions with antiphospholipid antibodies
- Chronic fatigue syndrome
- Demyelinative brain stem encephalitis
- Demyelinating neuropathy associated with monoclonal IgM
- Diabetes mellitus
- Dilated cardiomyopathy
- HIV infection, to reduce viral load
- HTLV-1-associated myelopathy
- Idiopathic dysautonomia, acute
- Inclusion body myositis
- Isolated IgA deficiency
- Isolated IgE deficiency
- Isolated IgG4 deficiency
- Isolated IgM deficiency
- Lumbosacral or brachial plexitis
- Monoclonal gammopathy
- Myocarditis, acute
- Neonatal isoimmune hemolytic jaundice
- Neonatal sepsis, prevention
- Ocular myasthenia
- Opsoclonus myoclonus
- Paraneoplastic cerebellar degeneration, sensory neuropathy, or encephalopathy
- Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
- Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)
- POEMS syndrome
- Postinfectious cerebellar ataxia
- Postoperative sepsis
- Pseudomembranous colitis
- Rheumatic fever, acute
- Sjogren's syndrome
- Spontaneous recurrent abortions, prevention
- Urticaria, chronic
- Urticaria, delayed pressure
- Vasculitides and antineutrophil antibody syndromes

Efficacy for these conditions has not been described in adequately designed studies. The available evidence is limited to case reports or case series, anecdotal reports, and open-label trials, or the available studies have failed to demonstrate a

positive treatment effect. Further well-designed studies are needed to establish the role of immune globulin in these conditions.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
90283	Immune globulin (IgIV), human, for intravenous use
90284	Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each

CPT® is a registered trademark of the American Medical Association

HCPCS Code	Description
J1459	Injection, immune globulin (Privigen®), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1551	Injection, immune globulin (Cutaquig), 100 mg
J1552	Injection, immune globulin (Alyglo), 500 mg
J1554	Injection, immune globulin (Asceniv™), 500 mg
J1555	Injection, immune globulin (Cuvitru®), 100mg
J1556	Injection, immune globulin (Bivigam®), 500 mg
J1557	Injection, immune globulin, (Gammaplex®), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1558	Injection, immune globulin (Xembify®), 100 mg
J1559	Injection, immune globulin (Hizentra®), 100 mg
J1561	Injection, immune globulin, (Gamunex®-C/Gammaked™), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
J1568	Injection, immune globulin, (Octagam®), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1569	Injection, immune globulin, (Gammagard® liquid), intravenous, nonlyophilized, (e.g., liquid), 500 mg
J1572	Injection, immune globulin, (Flebogamma®/Flebogamma® DIF), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1575	Injection, immune globulin/hyaluronidase, (Hyqvia®), 100 mg immune globulin
J1576	Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1599	Injection, immune globulin, intravenous, nonlyophilized (e.g., liquid), not otherwise specified, 500 mg

Diagnosis Code	Description
A48.3	Toxic shock syndrome
A49.9	Bacterial infection, unspecified
A87.8	Other viral meningitis
A87.9	Viral meningitis, unspecified
A88.8	Other specified viral infections of central nervous system
B20	Human immunodeficiency virus [HIV] disease
B25.0	Cytomegaloviral pneumonitis
B34.3	Parvovirus infection, unspecified
B97.35	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission

Diagnosis Code	Description
C90.02	Multiple myeloma in relapse
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.11	Chronic lymphocytic leukemia of B-cell type in remission
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
D59.11	Warm autoimmune hemolytic anemia
D69.3	Immune thrombocytopenic purpura
D69.51	Posttransfusion purpura
D69.59	Other secondary thrombocytopenia
D80.0	Hereditary hypogammaglobulinemia
D80.1	Nonfamilial hypogammaglobulinemia
D80.3	Selective deficiency of immunoglobulin G [IgG] subclasses
D80.4	Selective deficiency of immunoglobulin M [IgM]
D80.5	Immunodeficiency with increased immunoglobulin M [IgM]
D80.6	Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
D80.7	Transient hypogammaglobulinemia of infancy
D81.0	Severe combined immunodeficiency [SCID] with reticular dysgenesis
D81.1	Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
D81.2	Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
D81.6	Major histocompatibility complex class I deficiency
D81.7	Major histocompatibility complex class II deficiency
D81.82	Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]
D81.89	Other combined immunodeficiencies
D81.9	Combined immunodeficiency, unspecified
D82.0	Wiskott-Aldrich syndrome
D82.1	Di George's syndrome
D82.4	Hyperimmunoglobulin E [IgE] syndrome
D83.0	Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
D83.1	Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
D83.2	Common variable immunodeficiency with autoantibodies to B- or T-cells
D83.8	Other common variable immunodeficiencies
D83.9	Common variable immunodeficiency, unspecified
D84.81	Immunodeficiency due to conditions classified elsewhere
D84.821	Immunodeficiency due to drugs
D84.822	Immunodeficiency due to external causes
D84.89	Other immunodeficiencies
D89.2	Hypergammaglobulinemia, unspecified
D89.810	Acute graft-versus-host disease
D89.812	Acute on chronic graft-versus-host disease
D89.82	Autoimmune lymphoproliferative syndrome [ALPS]
D89.9	Disorder involving the immune mechanism, unspecified
E05.00	Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
E05.01	Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm
E31.0	Autoimmune polyglandular failure
G04.00	Acute disseminated encephalitis and encephalomyelitis, unspecified

Diagnosis Code	Description
G04.01	Postinfectious acute disseminated encephalitis and encephalomyelitis (postinfectious ADEM)
G04.81	Other encephalitis and encephalomyelitis
G04.90	Encephalitis and encephalomyelitis, unspecified
G05.3	Encephalitis and encephalomyelitis in diseases classified elsewhere
G05.4	Myelitis in diseases classified elsewhere
G11.3	Cerebellar ataxia with defective DNA repair
G25.82	Stiff-man syndrome
G35	Multiple sclerosis
G36.0	Neuromyelitis optica [Devic]
G40.811	Lennox-Gastaut syndrome, not intractable, with status epilepticus
G40.812	Lennox-Gastaut syndrome, not intractable, without status epilepticus
G40.813	Lennox-Gastaut syndrome, intractable, with status epilepticus
G40.814	Lennox-Gastaut syndrome, intractable, without status epilepticus
G61.0	Guillain-Barré syndrome
G61.81	Chronic inflammatory demyelinating polyneuritis
G61.89	Other inflammatory polyneuropathies
G61.9	Inflammatory polyneuropathy, unspecified
G62.89	Other specified polyneuropathies
G62.9	Polyneuropathy, unspecified
G65.0	Sequelae of Guillain-Barré syndrome
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation
G70.80	Lambert-Eaton syndrome, unspecified
G70.81	Lambert-Eaton syndrome in disease classified elsewhere
G73.1	Lambert-Eaton syndrome in neoplastic disease
L10.0	Pemphigus vulgaris
L10.2	Pemphigus foliaceus
L12.0	Bullous pemphigoid
L12.1	Cicatricial pemphigoid
L12.30	Acquired epidermolysis bullosa, unspecified
L12.35	Other acquired epidermolysis bullosa
L13.8	Other specified bullous disorders
L51.1	Stevens-Johnson syndrome
L51.2	Toxic epidermal necrolysis [Lyell]
L51.3	Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome
M30.3	Mucocutaneous lymph node syndrome [Kawasaki]
M33.00	Juvenile dermatomyositis, organ involvement unspecified
M33.01	Juvenile dermatomyositis with respiratory involvement
M33.02	Juvenile dermatomyositis with myopathy
M33.03	Juvenile dermatomyositis without myopathy
M33.09	Juvenile dermatomyositis with other organ involvement
M33.10	Other dermatomyositis, organ involvement unspecified
M33.11	Other dermatomyositis with respiratory involvement
M33.12	Other dermatomyositis with myopathy
M33.13	Other dermatomyositis without myopathy

Diagnosis Code	Description
M33.19	Other dermatomyositis with other organ involvement
M33.20	Polymyositis, organ involvement unspecified
M33.21	Polymyositis with respiratory involvement
M33.22	Polymyositis with myopathy
M33.29	Polymyositis with other organ involvement
M33.90	Dermatopolymyositis, unspecified, organ involvement unspecified
M33.91	Dermatopolymyositis, unspecified with respiratory involvement
M33.92	Dermatopolymyositis, unspecified with myopathy
M33.93	Dermatopolymyositis, unspecified without myopathy
M33.99	Dermatopolymyositis, unspecified with other organ involvement
M36.0	Dermato(poly)myositis in neoplastic disease
O26.40	Herpes gestationis, unspecified trimester
O26.41	Herpes gestationis, first trimester
O26.42	Herpes gestationis, second trimester
O26.43	Herpes gestationis, third trimester
O98.711	Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester
O98.712	Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester
O98.713	Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester
O98.719	Human immunodeficiency virus [HIV] disease complicating pregnancy, unspecified trimester
O98.72	Human immunodeficiency virus [HIV] disease complicating childbirth
O98.73	Human immunodeficiency virus [HIV] disease complicating the puerperium
T45.AX5A	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter
T45.AX5D	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter
T45.AX5S	Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela
P61.0	Transient neonatal thrombocytopenia
T86.00	Unspecified complication of bone marrow transplant
T86.01	Bone marrow transplant rejection
T86.02	Bone marrow transplant failure
T86.03	Bone marrow transplant infection
T86.09	Other complications of bone marrow transplant
T86.10	Unspecified complication of kidney transplant
T86.11	Kidney transplant rejection
T86.12	Kidney transplant failure
T86.13	Kidney transplant infection
T86.19	Other complication of kidney transplant
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status
Z29.89	Encounter for other specified prophylactic measures
Z29.9	Encounter for prophylactic measures, unspecified
Z48.290	Encounter for aftercare following bone marrow transplant
Z86.19	Personal history of other infectious and parasitic diseases
Z86.2	Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Z92.22	Personal history of monoclonal drug therapy
Z92.26	Personal history of immune checkpoint inhibitor therapy
Z92.29	Personal history of other drug therapy

Diagnosis Code	Description
Z94.0	Kidney transplant status
Z94.1	Heart transplant status
Z94.2	Lung transplant status
Z94.3	Heart and lungs transplant status
Z94.4	Liver transplant status
Z94.81	Bone marrow transplant status
Z94.82	Intestine transplant status
Z94.83	Pancreas transplant status
Z94.84	Stem cells transplant status

Background

Immune globulin, whether intravenous (IV) or subcutaneous (SC), is a sterile, purified preparation of human immunoglobulin derived from pooled human plasma from thousands of donors. Consisting primarily of immunoglobulin G, one of 5 classes of immunoglobulin (Ig), each batch of immune globulin (typically referred to as IVIG) provides immunomodulating peptides and antibodies against most exogenous antigens, many normal human proteins, and Fab, the antigen-binding region of autoantibodies. All currently available products contain high concentrations of IgG with subclass distribution corresponding to that of normal serum.

IVIG is considered a mainstay of treatment for immunodeficiency conditions and bullous skin disorders. It has been prescribed off-label to treat a wide variety of autoimmune and inflammatory neurologic conditions.

Clinical Evidence

Proven

Autoimmune Diseases

IVIG is beneficial for treatment of a number of autoimmune diseases based upon US Food and Drug Administration (FDA) approval, published practice guidelines, professional society evidence reviews, and/or randomized, controlled clinical trials. These include immune thrombocytopenic purpura and dermatomyositis and polymyositis.

Dermatology

A group of autoimmune diseases characterized by intraepidermal bullae formation (e.g., pemphigus vulgaris, bullous pemphigoid, dermatitis herpetiformis) are collectively referred to as autoimmune blistering skin disease. These are very fragile lesions that can rupture easily, leaving erosions. Autoimmune blistering skin diseases are prone to serious complications and in some cases can be fatal. The most common type of blistering skin disease is pemphigus vulgaris, which often affects the oral mucosa, and subsequent skin involvement. Immune globulin therapy is often needed for an extended period of time, often several months or years due to its chronic nature. According to ISBI practice guidelines, intravenous immune globulin (IVIG) is often given to patients who are hospitalized for Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is often treated with IVIG due to the serious, life-threatening nature of these conditions.

Hematology

IVIG is a first-line therapy for fetomaternal alloimmune thrombocytopenia and is recommended in international consensus guidelines. An article by Anderson et al. summarized the National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for hematologic conditions. The guidelines recommended IVIG use in the following: fetal-neonatal alloimmune thrombocytopenia; hemolytic disease of the newborn; HIV-associated thrombocytopenia; idiopathic thrombocytopenic purpura; and posttransfusion purpura.

Infectious and Infection-Related Diseases

IVIG is beneficial for a number of infectious and infection-related diseases based upon FDA approval, published practice guidelines, professional society evidence reviews, and/or randomized, controlled clinical trials. These include treatment of CMV-induced pneumonitis in solid organ transplants, treatment of staphylococcal toxic shock, treatment of bacterial infections in lymphoproliferative diseases, prevention of bacterial infections in patients with hypogammaglobulinemia

and/or recurrent bacterial infections associated with B-cell chronic lymphocytic leukemia (CLL). IVIG is also beneficial in chronic lymphocytic leukemia and multiple myeloma with reduced IgG and history of infections and prevention of bacterial infection in HIV-infected children. IVIG is also beneficial in patients with reduced IgG and history of infections for the prevention of infection following B-cell targeted therapies. Despite the lack of randomized controlled trials demonstrating that immune globulin (IG) therapy prevents infection in patients with hypogammaglobulinemia secondary to B-cell targeted therapies, Immune globulins may still be appropriate in certain cases depending on the degree of IgG deficiency, history and risk of infection, recency of B-cell targeted therapy, and other factors. Some experts recommend considering IVIG therapy when serum IgG is below 400 mg/dl or when it is 400 to 600 mg/dl and accompanied by serious, persistent, unusual, or recurrent infections.

Rheumatology

Due to the rarity of dermatomyositis and polymyositis, treatment recommendations supporting immune globulin have relied more on case reports and case series than on controlled. However, a randomized controlled trial comparing intravenous immune globulin (IVIG) to placebo demonstrated that IVIG treatment significantly improved dermatological symptoms in patients with Dermatomyositis, regardless of disease severity prior to treatment, suggesting that IVIG is effective, even in severe cases of dermatomyositis. Current treatment recommendations also recognize IVIG as the standard-of-care therapy for the initial treatment of Kawasaki Disease to reduce the rate of coronary artery aneurysms as well as the duration of fever and other symptoms.

Neuroimmunologic Disorders

Acute disseminated encephalomyelitis (ADEM), or postinfectious encephalomyelitis, is an autoimmune demyelinating disease that causes inflammation of myelin sheaths surrounding neurons in the brain. It is most common in children and young adults, and onset usually occurs after an infection. Signs and symptoms may include fever, headache, vomiting, lethargy, confusion, seizures, vision loss, weakness, or ataxia. The diagnosis is typically confirmed with cerebrospinal fluid analysis and MRI. First-line therapy for ADEM typically consists of corticosteroids, which are usually well-tolerated and effective. Expert consensus guidelines recommend IVIG and/or plasmapheresis as a viable second-line treatment option.

In 2016, the Myasthenia Gravis Foundation of America published consensus-based guidance for the management of myasthenia gravis (MG). Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. In regard to the use of IVIG, the task force concluded:

- Patients with refractory MG should be referred to a physician or a center with expertise in management of MG. In addition to immunosuppressant agents, chronic IVIG may also be used.
- IVIG is appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations.
- IVIG and PLEX are probably equally effective in the treatment of severe generalized MG.
- The efficacy of IVIG is less certain in milder MG or in ocular MG.
- PLEX may be more effective than IVIG in MuSK-MG.
- The use of IVIG as maintenance therapy can be considered for patients with refractory MG or for those in whom IS agents are relatively contraindicated.

In 2010, the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) published clinical guidelines for the management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). In regard to the diagnosis and treatment of CIDP with IVIG, the task force concluded:

- For induction of treatment, IVIG should be considered in sensory and motor CIDP in the presence of disabling symptoms (level A recommendation).
- For maintenance treatment, there is no sufficient evidence to recommend any particular drug. If response to IVIG is inadequate or result in adverse events, then other first-line treatment alternatives should be considered before combination treatments.
- **Electrodiagnostic criteria:**
 - Definite: At least one of the following:
 - § Motor distal latency prolongation $\geq 50\%$ above ULN in two nerves (excluding median neuropathy at the wrist from carpal tunnel syndrome); or
 - § Reduction of motor conduction velocity $\geq 30\%$ below LLN in two nerves; or
 - § Prolongation of F-wave latency $\geq 30\%$ above ULN in two nerves ($\geq 50\%$ if amplitude of distal negative peak CMAP $< 80\%$ of LLN values); or

- § Absence of F-waves in two nerves if these nerves have distal negative peak CMAP amplitudes $\geq 20\%$ of LLN+ ≥ 1 other demyelinating parameter in ≥ 1 other nerve; or
- § Partial motor conduction block: $\geq 50\%$ amplitude reduction of the proximal negative peak CMAP relative to distal, if distal negative peak CMAP $\geq 20\%$ of LLN, in two nerves, or in one nerve + ≥ 1 other demyelinating parameter in ≥ 1 other nerve; or
- § Abnormal temporal dispersion ($> 30\%$ duration increase between the proximal and distal negative peak CMAP) in ≥ 2 nerves; or
- § Distal CMAP duration (interval between onset of the first negative peak and return to baseline of the last negative peak) increase in ≥ 1 nerve (median ≥ 6.6 ms, ulnar ≥ 6.7 ms, peroneal ≥ 7.6 ms, tibial ≥ 8.8 ms) b + ≥ 1 other demyelinating parameter in ≥ 1 other nerve
- **Clinical diagnostic criteria:**
 - Inclusion criteria:
 - § **Typical CIDP:**
 - Chronically progressive, stepwise, or recurrent symmetric proximal and distal weakness and sensory dysfunction of all extremities, developing over at least 2 months; cranial nerves may be affected; and
 - Absent or reduced tendon reflexes in all extremities
 - § **Atypical CIDP (still considered CIDP but with different features):** One of the following, but otherwise as in (a) tendon reflexes may be normal in unaffected limbs:
 - Predominantly distal (distal acquired demyelinating symmetric, DADS); or
 - Asymmetric [multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), Lewis-Sumner syndrome]; or
 - Focal (e.g., involvement of the brachial or lumbosacral plexus or of one or more peripheral nerves in one upper or lower limb); or
 - Pure motor; or
 - Pure sensory (including chronic immune sensory polyradiculopathy affecting the central process of the primary sensory neuron)
 - Exclusion criteria:
 - § *Borrelia burgdorferi* infection (Lyme disease), diphtheria, drug or toxin exposure probably to have caused the neuropathy
 - § Hereditary demyelinating neuropathy
 - § Prominent sphincter disturbance
 - § Diagnosis of multifocal motor neuropathy
 - § IgM monoclonal gammopathy with high titer antibodies to myelin-associated glycoprotein
 - § Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. PNS lymphoma and amyloidosis may occasionally have demyelinating features

IVIG is beneficial for treatment of a number of neuroimmunologic diseases based upon FDA approval, published practice guidelines, professional society evidence reviews, and/or randomized, controlled clinical trials. These include chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, multifocal motor neuropathy, Lambert-Eaton myasthenic syndrome, IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathy, paraproteinemic neuropathy, stiff-person syndrome, myasthenia gravis, Lennox-Gastaut, and Rasmussen syndrome.

The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for neurologic conditions states that IVIG should be reserved as an option for patients with relapsing-remitting MS who fail, decline, or are not able to take standard immunomodulatory therapies. Based on consensus by the expert panel, IVIG is not recommended for treatment of primary or secondary progressive MS or for acute exacerbations of MS.

In their Guidelines for the Use of Intravenous Immunoglobulin in the Treatment of Neurological Diseases, the European Federation of Neurological Associations (EFNA) states that IVIG could be considered as a second or third-line therapy in RRMS if conventional immunomodulatory therapies are not tolerated because of side effects or concomitant diseases, and in particular in pregnancy where other therapies may not be used. IVIG cannot be recommended for treatment in secondary progressive MS. IVIG does not seem to have any valuable effect as add-on therapy to methylprednisolone for acute exacerbations and cannot be recommended as treatment for chronic symptoms in MS. In clinically isolated syndromes and in primary progressive MS, the EFNS Task Force concluded that there is not sufficient evidence to make any recommendations.

Similar findings were reported in a review of evidence by members of the Primary Immunodeficiency Committee of the AAAAI. The Committee concluded that IVIG might provide benefit for relapsing-remitting multiple sclerosis. A meta-

analysis and a review of multiple sclerosis clinical trials also found that evidence supports the use of IVIG for reduction of relapses in relapsing-remitting MS. The use of IVIG in relapsing-remitting MS should only be considered when other established therapies have failed or cannot be utilized.

In their review of relapse therapy and intermittent long-term therapy, the Neuromyelitis Optica Study Group (NEMOS) suggests IVIG therapy as an alternative for patients with contraindication to one of the other treatments (azathioprine and rituximab) or, particularly, in children.

The use of intravenous immunoglobulin (IVIG) as treatment for acute relapses in NMO was reported in a retrospective review of 10 patients.⁵⁴ In the majority of cases, IVIG was used due to lack of response to steroids with/without plasma exchange. Improvement was noted in five of 11 (45.5%) events; the remaining had no further worsening.

In a case series of eight Spanish patients with neuromyelitis optica (NMO), positive results were observed from bimonthly IVIG treatment (0.7 g/kg body weight/day for 3 days). The primary outcome measure in the study was the occurrence of serious adverse effects. Secondary outcome measures were changes in the yearly rate of attacks and in the degree of neurological disability measured with the Expanded Disability Status Scale (EDSS). All 8 patients were treated with IVIG; 5 had relapsing optic neuritis with or without myelitis and 3 had recurrent longitudinally extensive transverse myelitis (LETM). The mean age of onset was 20.5 years (range, 7-31 years) and 87.5% were female. The mean duration of the disease before beginning treatment was 9.0 years (range, 3-17 years). Following 83 infusions (range, 4-21 per patient) and a mean follow-up time of 19.3 months (range, 6-39 months), minor adverse events had occurred (headache in 3 patients and a mild cutaneous eruption in a single patient). The relapse rate decreased from 1.8 in the previous year to 0.006 during follow-up ($z = -2.5$, $p = 0.01$). The EDSS score fell from 3.3 (SD 1.3) to 2.6 (SD 1.5) ($z = -2.0$, $p = 0.04$). The investigators concluded that treatment with IVIG is safe and well-tolerated, and it may be used as a treatment alternative for NMO spectrum disorders.

Primary and Secondary Immune Deficiencies

IVIG is FDA-approved and indicated as replacement therapy in primary immune deficiencies.

Transplantation

Desensitization protocols that include intravenous immune globulin to eliminate antibodies in the blood prior to transplantation can increase the likelihood of transplantation success. Following solid organ (e.g., kidney, liver) transplantation, the possibility of an antibody-mediated organ rejection (AMR) that occurs through complement-mediated activation of macrophages and neutrophils causing, resulting in tissue damage and coagulation. Patients that are highly sensitized to human leukocyte antigens (HLAs) or ABO blood group antigens are more likely to have transplantation failure via AMR. Intravenous immune globulin (IVIG) therapy, as an adjunct to glucocorticoids, is used in most treatment protocols and is the standard of care for treating antibody-mediated rejection (AMR) in solid organ transplant recipients. Although randomized controlled studies are lacking, IVIG is recommended via expert opinion and community standards due to the seriousness of the condition and the lack of alternatives that have been proven effective.

Unproven

Acquired Hemophilia

An article by Anderson et al. summarized the National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for hematologic conditions. In the opinion of the expert panel, there is no convincing evidence of clinical benefit of IVIG in this disorder, and routine use is not recommended.

Adrenoleukodystrophy (ALD)

This is one of a group of genetic disorders called the leukodystrophies that cause damage to the myelin sheath surrounding nerve cells in the brain and progressive dysfunction of the adrenal gland. In one very small, randomized trial 6 patients received IVIG in addition to the dietary therapy while 6 received dietary therapy alone. No treatment effect of IVIG was demonstrated in this study. MRI findings and clinical status deteriorated in both groups. The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for neurologic conditions stated that IVIG should not be used for ALD.

Alzheimer's Disease

An open label dose-ranging study was conducted in 8 mild Alzheimer's disease (AD) patients. IVIG was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Anti-A β antibodies in the

serum from AD patients increased in proportion to IVIG dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma A β levels increased transiently after each infusion. Cerebrospinal fluid A β decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIG was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIG treatment. This study did not include an adequate number of AD patients to establish whether IVIG altered cognitive status.

Devi et al. reported on a retrospective investigation of patients (n = 10) with Alzheimer's disease treated with IVIG. Eight of the patients completed 6 months of treatment; two completed 3.5 months of treatment. Two patients developed a pruritic, maculopapular, generalized rash, resolving with appropriate treatment, but both continued with IVIG. Patients showed stability on neurocognitive scores overall, with trends toward decline on their WAIS verbal scale and full-scale intelligence scores (p < 0.1), as well as on the WAIS information (p < 0.1) subtest and the BNT (p = 0.1). Patients showed trends toward improvement on the WMS logical memory II recall (p < 0.1), WMS verbal paired associates (p = 0.15), and the WMS auditory delayed memory test (p = 0.1). It was found that IVIG was well tolerated and effective in this sample, with patients showing stability on neurocognitive test scores and trends toward improvement in some areas.

Further studies are needed to establish efficacy, to determine the optimal dosing regimen, and to confirm the safety of IVIG in the general population of AD patients.

Amyotrophic Lateral Sclerosis (ALS)

This is a disease characterized by progressive motor neuron degeneration, which manifests as weakness, spasticity, and muscle atrophy, usually beginning with the upper limbs. Two small-scale, uncontrolled studies (n = 7, 9) examined the use of IVIG for treatment of ALS; neither of these studies found a positive treatment effect. During and after treatment, all patients showed progressive deterioration at a pace similar to that observed before treatment or faster.^{34,107} The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for neurologic conditions stated that there is no role for IVIG in the treatment of ALS.⁶¹

Antiphospholipid Antibody Syndrome (APS) in Pregnancy

In their guideline for the treatment of recurrent first-trimester and second-trimester miscarriage, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends against the use of IVIG. There are several reports supporting a role for IVIG in the treatment of antiphospholipid antibody syndrome (APS), including in patients with APS undergoing in vitro fertilization. However, a meta-analysis of several modes of therapy (heparin, aspirin, glucocorticosteroids, and IVIG) in this clinical setting did not support any improved outcome with IVIG and a possible association with pregnancy loss or premature birth. A small randomized controlled study (n = 16) demonstrated no greater benefit from IVIG (plus heparin and aspirin) than from heparin and aspirin alone. Because the efficacy of IVIG has not been proved in appropriately designed studies, its use is not recommended for APS in pregnancy.

Asthma

Multiple randomized controlled trials have found no apparent advantage of IVIG over placebo. There have been observational studies and case reports suggesting a potential benefit, and a subgroup analysis performed in one of the RCTs did suggest that IVIG might reduce the amount of steroids needed, however, no additional research has been able to establish the usefulness of IVIG.

Atopic Dermatitis

IVIG treatment has shown success in small, open, uncontrolled trials of patients not responding to standard therapies. A small, randomized, evaluator-blinded trial (n = 10) did not support the routine use of IVIG in patients with atopic dermatitis.

Autism Spectrum Disorders

According to the review of evidence by members of the Primary Immunodeficiency Committee of the AAAAI, there are no formal randomized studies to evaluate the use of IVIG in autism. They found that two small, open-trial reports of autistic children placed on IVIG for 6 months showed no benefit. The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for neurologic conditions stated that the available evidence does not support the use of IVIG in the treatment of autism.

Autoimmune Neutropenia

Improvement in neutrophil counts has been described in several small series of patients with autoimmune neutropenia treated with IVIG, and anecdotal reports also suggest utility for IVIG in post-bone marrow transplantation neutropenia, which might be autoimmune in nature. It is unclear whether IVIG offers any advantage over corticosteroid therapy for the treatment of autoimmune neutropenia. The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for hematologic conditions found that "the evidence to support treatment with IVIG is sparse and of poor quality. However, there was some discussion regarding its use in rare circumstances when other options (e.g., intravenous antibiotics and G-CSF) have failed.

Bone Marrow Transplantation (BMT)

Prevention of Acute Graft-Versus-Host Disease (GVHD) After Autologous BMT

According to the Centers for Disease Control and Prevention, routine use of IVIG among autologous recipients is not recommended.

Prevention of Chronic Graft-Versus-Host Disease (GVHD) After Either Allogeneic or Autologous BMT

The use of IVIG was studied in a randomized, double-blind, dose-effect, placebo-controlled, multicenter trial in related allogeneic marrow transplantation. The trial included 200 patients receiving HLA-identical sibling marrow. IVIG-treated patients experienced no benefit versus placebo in reduction of incidence of infection, interstitial pneumonia, GVHD, transplantation-related mortality, or overall survival. There was a statistically higher incidence of grade 3 (severe) veno-occlusive disease associated with high-dose IVIG. The patients given higher doses of IVIG also had more side effects, such as fever and chills. The data does not support a recommendation for IVIG in HLA-identical sibling bone marrow transplants.

Prevention of Infection After Autologous BMT

According to the Centers for Disease Control and Prevention, routine use of IVIG among autologous recipients is not recommended.

Chronic Fatigue Syndrome

Numerous anecdotal reports have shown subjective benefits of IVIG for chronic fatigue syndrome. However, a double-blind, placebo-controlled trial demonstrated IVIG was not effective in the treatment of typical chronic fatigue syndrome.

Diabetes Mellitus

Per an update of the 2006 American Academy of Allergy, Asthma & Immunology guideline and centers on the use of standard immunoglobulin preparations specifically manufactured for intravenous (IV) or subcutaneous (SC) administration, immunoglobulin is unlikely to be beneficial in treating autoimmune diabetes mellitus.

Dilated Cardiomyopathy

According to a review of evidence by the members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, "Case reports suggest that patients with acute myocarditis benefit from high-dose IVIG. Placebo-controlled trials evaluating the benefit of IVIG use in recent-onset cardiomyopathy showed no benefit over placebo. High-dose IVIG might provide help to patients with acute myocarditis but has no therapeutic role in recent-onset dilated cardiomyopathy.

HIV Infection, to Reduce Viral Load

Although IVIG is FDA-approved for reducing the incidence of secondary infection in HIV-infected children, its use in treating HIV infection per se has not been as widely evaluated. A study examining the effect of a 2 g/kg IVIG dose on viral load found that p24 antigen levels and numbers of HIV RNA copies were significantly increased after treatment. Thus, IVIG might be useful for preventing bacterial infections but should not be considered an antiviral therapy in the HIV-infected patient.

Inclusion Body Myositis

The treatment of inclusion body myositis (IBM) with IVIG has been studied in two randomized, double-blind, placebo controlled trials. In the first study (n = 19), no statistically significant treatment differences were noted between IVIG and placebo. In the second study (n = 22), outcome measures showed a trend towards improvement with IVIG. Based on

these studies, IVIG is not recommended as routine therapy for IBM due to the variability of response and expense of therapy.

IVIG for inclusion body myositis was also assessed in open-label trials, but generalized conclusions or recommendations are not presently possible.

The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for neurologic conditions stated that IVIG should not be used for the treatment of IBM.

In their Guidelines for the Use of Intravenous Immunoglobulin in the Treatment of Neurological Diseases, the European Federation of Neurological Societies (EFNS) states that IVIG cannot be recommended for the treatment of sporadic IBM.

In their evidence-based guideline on IVIG in the treatment of neuromuscular disorders, the American Academy of Neurology states that there is insufficient evidence to support the use of IVIG in IBM.

Isolated IgA Deficiency

This is the most common immunodeficiency disorder characterized by a deficiency of IgA with normal levels of other immunoglobulin classes. Isolated IgA deficiency is marked by recurrent sinusitis, bronchitis, and pneumonia, and recurrent diarrhea, although many patients have no symptoms. Management of selective IgA deficiency is limited to treating associated infections. Some advocate prophylactic daily doses of antibiotics for patients with multiple, recurrent infections. No intervention is available to either replace IgA via infusion or increase production of native IgA. Selective IgA deficiency is not an indication for IVIG replacement therapy, although in some cases poor specific IgG antibody production, with or without IgG2 subclass deficiency, might coexist; in these patients IVIG might be required. Intravenous administration of IVIG can pose a risk of anaphylaxis for IgA-deficient patients who have IgE anti-IgA antibodies or reactions caused by complement activation if IgG anti-IgA antibodies are present.

Isolated IgG4 Deficiency

IgG4 deficiency may be found in 10-15% of the general population. The significance of isolated, or selective, IgG4 deficiency is unclear.

Myocarditis, Acute

According to a review of evidence by the members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, "Case reports suggest that patients with acute myocarditis benefit from high-dose IVIG. Placebo-controlled trials evaluating the benefit of IVIG use in recent-onset cardiomyopathy showed no benefit over placebo. High-dose IVIG might provide help to patients with acute myocarditis but has no therapeutic role in recent-onset dilated cardiomyopathy.

Neonatal Sepsis

Prevention

A recent meta-analysis found that there is insufficient evidence to support the routine administration of IVIG to prevent mortality in infants with suspected or subsequently proved neonatal infection.¹¹⁹ Despite encouraging trials of IVIG as an adjunct to enhance the antibacterial defenses of premature newborn infants, there are substantial contradictory data and insufficient overall evidence to support the routine administration of IVIG in infants at risk for neonatal infection.

Ocular Myasthenia

Myasthenia gravis is an autoimmune disorder in which the body's own antibodies block the transmission of nerve impulses to muscles, causing fluctuating weakness and muscles that tire easily. Approximately half of patients present with purely ocular symptoms (ptosis, diplopia), so-called ocular myasthenia. Between 50% and 60% of people who have ocular myasthenia will progress to develop generalized myasthenia gravis (GMG) and weakness affecting other muscles. The aims of treatment for ocular myasthenia are to return the person to a state of clear vision and to prevent the development, or limit the severity of GMG. Treatments proposed for ocular myasthenia include drugs that suppress the immune system including corticosteroids and azathioprine, thymectomy, and acetylcholinesterase inhibitors. There are retrospective, but no prospective, data, which indicate that immunosuppressive treatment of ocular myasthenia may decrease the likelihood of developing GMG. It is not clear from these studies whether treatment actually reduces the incidence of GMG, delays its onset, or just masks its symptoms. Plasmapheresis and intravenous immune globulin are used for the short-term management of severe GMG, but available evidence does not indicate that either therapy has a role in patients with ocular myasthenia.

Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS)

Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical diagnosis based on a collection of symptoms with an abrupt onset, including obsessions, compulsions, or restricted food intake, often accompanied with other neuropsychiatric symptoms such as anxiety, depression, tics, or personality changes. Although it has been suggested to be related to infection or autoimmune processes, no specific biomarker has yet been identified for diagnosing this condition. Similarly, streptococcal infections have also been correlated with induced exacerbation of symptoms in some children with obsessive-compulsive and tic disorders, also possibly on an autoimmune basis. The correlated syndrome is referred to as pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). There have been limited high quality evidence to support the use of immune globulins for PANS/PANDAS. The American Academy of Pediatrics (AAP) has developed a clinical report on PANS and PANDAS based on a comprehensive literature review and an analysis of its findings. The AAP considers the use of IgG an unproven treatment that is not recommended. If used, its use should be limited to carefully controlled clinical trials in order to improve our understanding of, and evidence for, effective treatment for PANS. A separate 2018 systematic review of treatments for PANS was done by Sigra and colleagues. The review concluded that the evidence for the benefit of IgG therapy was inconclusive due to a variety of reasons, including, but not limited to, poor study designs, small numbers of trial participants, a high risk of bias, and conflicting results. Additionally, the authors noted that rigorously conducted research regarding treatments for PANDAS is scarce, and higher quality studies that do exist indicate low support for its use. One high-quality randomized, double-blind, placebo-controlled trial studied the efficacy of IVIG in children diagnosed with PANS/PANDAS. The primary outcome measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impressions-Improvement (CGI-I) rating. During the double-blind phase, the mean decrease in CY-BOCS score was 24% \pm 31% in the IVIG group (n = 17) and 12% \pm 27% in the placebo group (n = 18), with six responders in the IVIG group (35%) versus four (22%) in the placebo group; these differences were not statistically significant. Several recent studies have been published studying the efficacy of IVIG in PANS/PANDAS. These studies, despite their promising results, have several notable limitations, yielding low-quality evidence that is not considered reliable. Most notably, these studies are not blinded, randomized, nor placebo controlled. Other limitations include poor study design, inconsistent results comparing averages of all participants, small sample size, lack of a control group, inherent risk for bias, inconsistent assessments across and within the studies, and a heterogeneous patient population with differing durations of illness and treatment protocols. Further research, specifically high-quality trials, i.e., randomized, double-blinded, and placebo controlled, are needed before immune globulin becomes a standard of therapy.

POEMS Syndrome

Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome also known as Crow-Fukase syndrome or osteosclerotic myeloma is a unique multisystem disorder strongly associated with plasma cell dyscrasia. Only anecdotal experience is available for assessing IVIG as treatment for POEMS syndrome. The National Advisory Committee on Blood and Blood Products of Canada (NAC) and Canadian Blood Services panel of national experts' evidence-based practice guideline on the use of IVIG for neurologic conditions stated there is no role for IVIG in the treatment of POEMS syndrome. Per an update of the 2006 American Academy of Allergy, Asthma & Immunology guideline and centers on the use of standard immunoglobulin preparations specifically manufactured for intravenous (IV) or subcutaneous (SC) administration, immune globulin is not recommended for use in POEMS syndrome. In addition, polyneuropathy associated with IgM monoclonal gammopathy is an example of a disease in which IVIG was ineffective, or even had negative effects.

Rotaviral Enterocolitis

Only small studies and case reports have suggested that oral immune globulin may have a beneficial effect on diarrhea related to rotaviral enterocolitis in infants and young children. Intravenous and/or subcutaneous immune globulins were not studied.

Sjogren's Syndrome

IVIG has shown some efficacy in Sjogren's syndrome. Most of the reports have focused on associated dysautonomia or neuropathy although they have been very small case studies. One case study was of a 41 year old man with severe sympathetic and parasympathetic autonomic dysfunction as a consequence of acetylcholine receptor antibodies and Sjogren's syndrome who failed to respond to IVIG. Larger, blinded, and controlled studies of IVIG are required regarding its efficacy for Sjogren's syndrome.

Spontaneous Recurrent Abortions, Prevention

Results of treatment with IVIG have been conflicting. While prospective studies have suggested that the use of IVIG in pregnant women with a history of recurrent abortions imparted a protective benefit, other studies suggested no benefit.

The members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology assessed a review from a number of high-quality randomized, placebo-controlled, multicenter studies and found that, "Given the review of randomized trials, cumulative current evidence does not presently support the use of IVIG for the prevention of recurrent spontaneous abortions."

Urticaria

An autoimmune process is implicated in about one third of patients with chronic urticaria. Most case reports of successful treatment of chronic urticaria occur in those in whom an autoimmune mechanism is involved. However, in other case reports, patients did not respond or relapsed shortly after the completion of therapy. Delayed-pressure urticaria is a variant of chronic urticaria that is also difficult to treat. The use of IVIG in patients with delayed-pressure urticaria was conducted as an open-label trial; one third of the enrolled patients experienced remission, another third experienced some benefit, and the rest did not respond. Per an update of a 2006 American Academy of Allergy, Asthma & Immunology guideline, there is no clear evidence that the use of IVIG benefits patients with chronic urticaria, and additional placebo-controlled studies with long-term follow-up are needed.

Vasculitides and Antineutrophil Antibody Syndromes

The efficacy of IVIG in the treatment of anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) was assessed in a randomized, placebo-controlled trial. Thirty four patients (24 diagnosed with Wegener's granulomatosis, 10 diagnosed with microscopic polyangiitis) were randomized to a single course of either 400 mg/kg/day IVIG or placebo for 5 days. A therapeutic response was defined as a 50% decrease in the Birmingham Vasculitis Activity Score (BVAS) at 3 months. A therapeutic response was found in 14/17 patients who received IVIG and 6/17 patients who received placebo (OR = 8.56, 95% CI = 1.74-42.2, p = 0.015). The C-reactive protein (CRP) level decrease was significantly greater at 2 weeks and one month in the IVIG group compared to the placebo group. After 3 months, there was no difference in disease activity or CRP level between the IVIG and placebo groups. In addition, small open label trials of IVIG found some clinical benefit as an alternative therapeutic agent. Results were reported as transient in several of these. Additional randomized controlled trials will need to be conducted to determine its place in therapy.

Professional Societies

Immune Deficiency Foundation (IDF)

There are more than 300 primary immunodeficiency diseases (PIDs) recognized by the World Health Organization. The following diseases are PIDs and thus are proven indications for immune globulin (list not all inclusive). Additional PID information can be found at the IDF website: primaryimmune.org. [Back to criteria](#)

- Autosomal recessive agammaglobulinemia
- Autosomal recessive hyperimmunoglobulin M syndrome (HIM)
- Bruton's disease
- Chronic mucocutaneous moniliasis (CMC or APCED)
- Combined immunodeficiency disorders:
 - Ataxia-telangiectasia
 - DiGeorge syndrome
 - Nijmegen breakage syndrome
 - WHIM (warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis) syndrome
 - Wiskott Aldrich syndrome
- Common variable immunodeficiency (CVID)
- Congenital hypogammaglobulinemia late onset, ICOS impaired
- Congenital/X-linked agammaglobulinemia
- Good syndrome (immunodeficiency with thymoma)
- Hyperimmunoglobulinemia E syndrome
- Hypogammaglobulinemia
- ICF syndrome
- Polyendocrinopathy and enteropathy (IPEX)
- Selective IgG subclass deficiencies (persistent absence of IgG1, IgG2, and/or IgG3)
- Selective IgM deficiency
- Severe combined immunodeficiency
- Specific antibody deficiency
- Transient hypogammaglobulinemia of infancy, short-term treatment of recurrent severe bacterial infections
- X-linked immunodeficiency with hyperimmunoglobulin M

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

There are currently eight clinical indications for which IVIG has been licensed by the United States Food and Drug Administration (FDA). The indications can be summarized as follows:

- Treatment of primary immunodeficiencies such as common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
- Prevention of bacterial infections in patients with hypogammaglobulinemia and recurrent bacterial infection caused by B-cell chronic lymphocytic leukemia.
- Prevention of coronary artery aneurysms in Kawasaki disease (KD).
- Prevention of infections, pneumonitis, and acute graft-versus-host disease (GVHD) after bone marrow transplantation.
- Reduction of serious bacterial infection in children with human immunodeficiency virus (HIV).
- Increase of platelet counts in idiopathic thrombocytopenic purpura to prevent or control bleeding.
- Improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse in chronic inflammatory demyelinating polyneuropathy (CIDP).
- Maintenance therapy to improve muscle strength and disability in adult patients with multifocal motor neuropathy.

Subcutaneous human immune globulin products are FDA approved for the treatment of patients with primary immune deficiency. This includes, but not is limited to, diagnoses such as common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

References

1. ACOG Practice Bulletin: Thrombocytopenia in pregnancy. Number 166, September 2016. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. *Obstet Gynecol.* 2016 Sep;128(3):e43-53.
2. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. *Arthritis Care Res (Hoboken)*. 2020;72(4):461-488. doi:10.1002/acr.24130.
3. Brocklehurst P, Farrell B, King A, et al. Treatment of Neonatal Sepsis with Intravenous Immune Globulin. *N Engl J Med* 2011;365:1201-11.
4. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis *Ann Rheum Dis.* 2016 Aug 11.
5. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. *Cochrane Database Syst Rev* 2005;CD002859.
6. Fazekas F. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. PRIVIG Study Group. *Neurology.* 2008;71(4):265.
7. Flebogamma DIF [prescribing information]. Barcelona, Spain: Instituto Grifols, S.A.; September 2019.
8. Gammagard Liquid [prescribing information]. Lexington, MA: Baxalta US Inc.; January 2024.
9. Gammagard S/D [prescribing information]. Lexington, MA: Baxalta US Inc.; March 2023.
10. Gammaked [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics Inc.; January 2020.
11. Gammplex [prescribing information]. Elstree, UK: Bio Products Laboratory Limited; November 2021.
12. Gamunex-C [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics Inc.; January 2020.
13. Hizentra [prescribing information]. Bern, Switzerland: CSL Behring AG; April 2021.
14. Octagam [prescribing information]. Vienna, Austria: Octapharma; April 2022.
15. Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. *Cochrane Database of Systematic Reviews* 2010, Issue 3. Art. No.: CD001239.
16. Privigen [prescribing information]. Bern, Switzerland: CSL Behring AG; March 2022.

17. Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2011 Apr. 18 p. (Green-top guideline; no. 17).
18. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities, Version 1.2024. Accessed March 20, 2024.
19. Cuvitru [prescribing information]. Lexington, MA: Baxalta US Inc.; March 2023.
20. Bivigam [prescribing information]. Boca Raton, FL: ADMA Biologics; March 2024.
21. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD005081. DOI: 10.1002/14651858.CD005081.pub3.
22. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13:106-111.
23. Maddison P. Treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 2012 Dec;1275:78-84. doi: 10.1111/j.1749-6632.2012.06769.x.
24. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010 Jun;125(6):1354-1360.e4. doi: 10.1016/j.jaci.2010.02.040. Epub 2010 May 14.
25. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010 Oct;137(1):21-30. doi: 10.1016/j.clim.2010.06.012. Epub 2010 Aug 1.
26. Bonilla FA, Khan DA, Ballas ZK et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78.
27. HyQvia [prescribing information]. Lexington, MA: Baxalta US Inc; January 2024. April 2023.
28. Feasby T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21 (2 Suppl 1):S57-107.
29. Heinze E. Immunoglobulins in children with autoimmune diabetes mellitus. Clin Exp Rheumatol 1996;14(suppl):S99-102.
30. Asceniv [prescribing information]. Boca Raton, FL: ADMA Biologics; April 2019.
31. Cutaquig [prescribing information]. Vienna, Austria: Octapharma; November 2021.
32. Xembify [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
33. Williams KA, Swedo SE, Farmer CA, et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. J Am Acad Child Adolesc Psychiatry 2016; 55:860.
34. Vacca A, Melaccio A, Sportelli A, et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018 Jun;191:110-115.
35. Bussel JB, Berkowitz RL, Hung C, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010 Aug;203(2):135.e1-14.
36. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1-S46. doi:10.1016/j.jaci.2016.09.023.
37. Hrabak T, Calabria CW. Multiple treatment cycles of high-dose intravenous immunoglobulin for chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2010;105(3):245-246. doi:10.1016/j.anai.2010.05.018.
38. Ghadiri N, Reekie IR, Gordon I, et al. Systematic review of clinical practice guidelines for uveitis. BMJ Open Ophthalmol. 2023;8(1):e001091. Published 2023 Jan 5. doi:10.1136/bmjophth-2022-001091. Autoimmune Uveitis.
39. Alyglo [prescribing information]. Teaneck, NJ: GC Biopharma Corp; December 2023.
40. Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012 Feb;45(1):111-8. doi: 10.3109/08916934.2011.606452. Epub 2011 Sep 19. PMID: 21923613.
41. Chee SN, Murrell DF. The use of intravenous immunoglobulin in autoimmune bullous diseases. Immunol Allergy Clin North Am. 2012 May;32(2):323-30, viii. doi: 10.1016/j.iac.2012.04.012. Epub 2012 Apr 18. PMID: 22560145.

42. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant.* 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019[PubMed 19747629].
43. Van den Bergh PYK, Doorn PAV, Hadden RDM, et al. European Academy of Neurological Societies/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force — Second Revision. *J Peripher Nerv Syst.* 2021;26:242–268.
44. Tavee J, Brannagan TH 3rd, Lenihan MW, Muppidi S, Kellermeyer L, D Donofrio P; AANEM. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. *Muscle Nerve.* 2023 Oct;68(4):356-374. doi: 10.1002/mus.27922. Epub 2023 Jul 11. PMID: 37432872.
45. Goyal NA, Karam C, Sheikh KA, Dimachkie MM. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. *Muscle Nerve.* 2021 Sep;64(3):243-254. doi: 10.1002/mus.27356. Epub 2021 Jul 14. PMID: 34260074; PMCID: PMC8457117.
46. Kotton, Camille N. MD, Kumar, D, Caliendo, AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation* 102(6):p 900-931, June 2018. | DOI: 10.1097/TP.0000000000002191.
47. Aggarwal R, Charles-Schoeman C, Schessl J, et al. ProDERM Trial Group. Trial of Intravenous Immune Globulin in Dermatomyositis. *N Engl J Med.* 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912. PMID: 36198179.
48. Panel on Opportunistic Infections in Children With and Exposed to HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection>. Accessed November 11, 2024.
49. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv.* 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812.
50. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. *Neurology.* 2021;96(3):114-122. doi:10.1212/WNL.0000000000001124.
51. Rajvanshi N, Kumar P, Goyal JP. Global Initiative for Asthma Guidelines 2024: An Update. *Indian Pediatr.* 2024;61(8):781-786.
52. Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management [published correction appears in *J Neurol.* 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2]. *J Neurol.* 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z.
53. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol.* 2009;60(4):595-603. doi:10.1016/j.jaad.2008.09.052 #3.
54. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. *J Am Acad Dermatol.* 2001;45(5):679-690. doi:10.1067/mjd.2001.116339.
55. Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. *Rheumatology (Oxford).* 2022 May 5;61(5):1760-1768. doi: 10.1093/rheumatology/keac115. PMID: 35355064; PMCID: PMC9398208.
56. Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. *Mod Rheumatol.* 2019;29(1):1-19. doi:10.1080/14397595.2018.1521185.
57. Donato H. Neonatal thrombocytopenia: A review. I. Definitions, differential diagnosis, causes, immune thrombocytopenia. *Arch Argent Pediatr.* 2021 Jun;119(3):e202-e214. English, Spanish. doi: 10.5546/aap.2021.eng.e202. PMID: 34033425.
58. Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez Q JH. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis. *J Clin Neuromuscul Dis.* 2016;18(1):1-11. doi:10.1097/CND.0000000000000119.
59. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association [published correction appears in *Circulation.* 2019 Jul 30;140(5):e181-e184. doi: 10.1161/CIR.0000000000000703]. *Circulation.* 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484.

60. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. *Neurology*. 1996;47(3):678-683.[PubMed 8797464].
61. Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. *Mult Scler*. 2004;10(1):89-91. doi:10.1191/1352458504ms978sr.
62. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790.
63. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. *Neurology*. 2011;76(23):2017-2023.[PubMed 21562253].
64. Gajdos P, Tranchant C, Clair B, et al; Myasthenia Gravis Clinical Study Group. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. *Arch Neurol*. 2005;62(11):1689-1693.[PubMed 16286541].
65. Skeie GO, Apostolski S, Evoli A, et al; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. *Eur J Neurol*. 2010;17(7):893-902.[PubMed 20402760].
66. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. *JAMA*. 1995;273(23):1865-1870.
67. Cheng EY, Everly MJ, Kaneku H, et al. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients. *Transplantation*. 2017;101(4):873-882. doi:10.1097/TP.0000000000001391.
68. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant*. 2009;9 Suppl 3:S1-S155. doi:10.1111/j.1600-6143.2009.02834.x.
69. Baradaran H, Dashti-Khavidaki S, Taher M, Talebian M, Nasiri-Toosi M, Jafarian A. Antibody-Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review. *J Clin Pharmacol*. 2022;62(2):254-271. doi:10.1002/jcph.1963.
70. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. *J Heart Lung Transplant*. 2010;29(9):973-980. doi:10.1016/j.healun.2010.05.006[PubMed 20558084].
71. Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. *J Heart Lung Transplant*. 2013;32(10):1034-1040. doi:10.1016/j.healun.2013.07.004[PubMed 23953920].
72. de Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive C4d staining and anti-donor antibodies related to worse outcome for patients. *Am J Transplant*. 2010;10(7):1660-1667. doi:10.1111/j.1600-6143.2010.03079.x[PubMed 20455878].
73. Parajuli S, Alagusundaramoorthy S, Aziz F, et al. Outcomes of pancreas transplant recipients with de novo donor-specific antibodies. *Transplantation*. 2019;103(2):435-440. doi:10.1097/TP.0000000000002339[PubMed 29994978].
74. Uva PD, Quevedo A, Roses J, et al. Anti-HLA donor-specific antibody monitoring in pancreas transplantation: role of protocol biopsies. *Clin Transplant*. 2020;34(8):e13998. doi:10.1111/ctr.13998[PubMed 32492226].
75. Babiker A, Kadri SS. ICU Management of Invasive β -Hemolytic Streptococcal Infections. *Infect Dis Clin North Am*. 2022;36(4):861-887. doi:10.1016/j.idc.2022.07.007.
76. Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. *J Neurol*. 2005;252 Suppl 1:I19-I25. doi:10.1007/s00415-005-1105-4.
77. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev*. 2007 Apr;21(2 Suppl 1):S9-56. doi: 10.1016/j.tmr.2007.01.001. PMID: 17397769.
78. Patel TK, Patel PB, Thakkar S. Comparison of effectiveness of interventions in reducing mortality in patients of toxic epidermal necrolysis: A network meta-analysis. *Indian J Dermatol Venereol Leprol*. 2021;87(5):628-644. doi:10.25259/IJDVL_605_19.
79. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016 (print summary - Full guidelines available at <http://dx.doi.org/10.1016/j.bjps.2016.01.034>). *J Plast Reconstr Aesthet Surg*. 2016;69(6):736-741. doi:10.1016/j.bjps.2016.04.018.

80. Venkatesan A, Michael BD, Probasco JC, Geocadin RG, Solomon T. Acute encephalitis in immunocompetent adults. *Lancet*. 2019;393(10172):702-716. doi:10.1016/S0140-6736(18)32526-1.
81. Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. *J Neurol Neurosurg Psychiatry*. 2021;92(7):757-768. doi:10.1136/jnnp-2020-325300.
82. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. *Blood Rev*. 2020;41:100648. doi:10.1016/j.blre.2019.100648.
83. Schneider BJ, Naidoo J, Santomaso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. *J Clin Oncol*. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440[PubMed 34724392].
84. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2015;36(42):2921-2964. doi:10.1093/eurheartj/ehv318.
85. Colvin MM, Cook JL, Chang PP, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Cardiovascular Surgery and Anesthesia. Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association. *Circulation*. 2019;139(12):e553-e578. doi:10.1161/CIR.0000000000000598[PubMed 30776902].
86. Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: an ISHLT consensus document. *J Heart Lung Transplant*. 2018;37(5):537-547. doi:10.1016/j.healun.2018.01.1291[PubMed 29452978].
87. Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, et al. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised doubleblinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. *J Neurol Neurosurg Psychiatry* 2015 Sep 29. pii: jnnp-2015-311486. <http://dx.doi.org/10.1136/jnnp-2015-311486>. [Epub ahead of print].
88. Melamed I, Kobayashi RH, O'Connor M, Kobayashi AL, Schechterman A, Heffron M, Canterberry S, Miranda H, Rashid N. Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome. *J Child Adolesc Psychopharmacol*. 2021 Mar;31(2):118-128. doi: 10.1089/cap.2020.0100. Epub 2021 Feb 18. PMID: 33601937. NCT03348618.
89. Eremija J, Patel S, Rice S, Daines M. Intravenous immunoglobulin treatment improves multiple neuropsychiatric outcomes in patients with pediatric acute-onset neuropsychiatric syndrome. *Front Pediatr*. 2023 Oct 16;11:1229150. doi: 10.3389/fped.2023.1229150. PMID: 37908968.
90. Hajjari P, Oldmark MH, Fernell E, Jakobsson K, Vinsa I, Thorsson M, Monemi M, Stenlund L, Fasth A, Furuholm C, Johnels JÅ, Gillberg C, Johnson M. Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children. *BMC Psychiatry*. 2022 Aug 6;22(1):535. doi: 10.1186/s12888-022-04181-x. PMID: 35933358.
91. American Academy of Pediatrics Board of Directors; Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Report. *Pediatrics* 2024; 10.1542/peds.2024-070334.
92. Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: a systematic review. *Neurosci Biobehav Rev*. 2018;86:51-65.
93. Lieberman L, Greinacher A, Murphy MF, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. *Br J Haematol*. 2019;185(3):549-562. doi:10.1111/bjh.15813.
94. Massa S, Fracchiolla A, Neglia C, Argentiero A, Esposito S. Update on Acute Disseminated Encephalomyelitis in Children and Adolescents. *Children (Basel)*. 2021;8(4):280. Published 2021 Apr 6. doi:10.3390/children8040280.
95. Wang CX. Assessment and Management of Acute Disseminated Encephalomyelitis (ADEM) in the Pediatric Patient. *Paediatr Drugs*. 2021;23(3):213-221. doi:10.1007/s40272-021-00441-7.
96. Los-Arcos I, Iacoboni G, Aguilar-Guisado M, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. *Infection*. 2021;49(2):215-231. doi:10.1007/s15010-020-01521-5.

97. Werth VP, Aggarwal R, Charles-Schoeman C, et al. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study. *EClinicalMedicine*. 2023;64:102234. Published 2023 Oct 2. doi:10.1016/j.eclinm.2023.102234.
98. Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. *Arthritis Care Res (Hoboken)*. 2022;74(4):538-548. doi:10.1002/acr.24838.
99. Colvin M, Cook, J, Chang PP, et al. Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. *Circulation* 2019, 139: e553-e78. DOI:10.1161/CIR.0000000000000598.
100. Hart A, Singh D, Brown SJ, Wang JH, Kasiske BL. Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review. *Clin Transplant*. 2021;35(7):e14320. doi:10.1111/ctr.14320.
101. ISBI Practice Guidelines Committee; Advisory Subcommittee; Steering Subcommittee. ISBI Practice Guidelines for Burn Care, Part 2. *Burns*. 2018;44(7):1617-1706. doi:10.1016/j.burns.2018.09.012.
102. Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. *Br J Dermatol*. 2017;177(5):1170-1201. doi:10.1111/bjd.15930.

Policy History/Revision Information

Date	Summary of Changes
04/01/2025	<p>Application</p> <p>Arizona</p> <ul style="list-style-type: none"> • Added instruction to refer to the state’s Medicaid clinical policy and use drug-specific criteria if available for the specific product; otherwise this Medical Benefit Drug Policy applies <p>Coverage Rationale</p> <ul style="list-style-type: none"> • Added language to indicate: <ul style="list-style-type: none"> ○ Immune globulin is proven for the treatment of: <ul style="list-style-type: none"> § Acute disseminated encephalomyelitis (ADEM) § Encephalitis, immune checkpoint inhibitor-induced, severe or progressive § Parvovirus B19 infection, treatment, immunocompromised host (solid organ transplant recipient or HIV-related) § Warm autoimmune hemolytic anemia ○ Immune globulin is medically necessary for the treatment of the following conditions when all the listed criteria are met: <ul style="list-style-type: none"> Acute Disseminated Encephalomyelitis (ADEM) <ul style="list-style-type: none"> § Diagnosis of acute disseminated encephalomyelitis (ADEM) § History of failure, contraindication, or intolerance to intravenous glucocorticoids Encephalitis, Immune Checkpoint Inhibitor-Induced, Severe or Progressive <ul style="list-style-type: none"> § Diagnosis of encephalitis, immune checkpoint inhibitor-induced, severe or progressive § History of failure, contraindication, or intolerance to glucocorticoids (e.g., methylprednisolone) § The use of the immune checkpoint inhibitor has been interrupted § Prescribed by or in consultation with a neurologist Warm Autoimmune Hemolytic Anemia <ul style="list-style-type: none"> § Diagnosis of warm autoimmune hemolytic anemia § Other types of autoimmune hemolytic anemia have been ruled out § History of failure, contraindication, or intolerance to glucocorticoids (e.g., prednisone, methylprednisolone) § History of failure, contraindication, or intolerance to at least one of the following: <ul style="list-style-type: none"> – Rituximab – Immunosuppressive agent [e.g., azathioprine, cyclophosphamide, cyclosporin A, danazol, mycophenolate mofetil (MMF), sirolimus, Tavalisse (fostamatinib)] § Patient is still transfusion-dependent at a minimum of two weeks after initiation of rituximab or a second-line immunosuppressive agent § Immune globulin will be used as an adjunct to other therapies ○ Immune globulin is unproven and not medically necessary for the treatment of pediatric acute-onset neuropsychiatric syndrome (PANS)

Date	Summary of Changes
	<ul style="list-style-type: none"> • Replaced language indicating: <ul style="list-style-type: none"> ○ “Immune globulin is proven for <i>renal</i> transplantation, prevention, or treatment of acute antibody-mediated rejection (i.e., B-cell mediated or humoral rejection)” with “immune globulin is proven for <i>solid organ</i> transplantation, <i>desensitization</i>, prevention, or treatment of acute antibody-mediated rejection (i.e., B-cell mediated or humoral rejection)” ○ “Immune globulin is unproven and not medically necessary for the treatment of asthma, <i>non-steroid dependent</i>” with “immune globulin is unproven and not medically necessary for the treatment of asthma” • Removed language indicating: <ul style="list-style-type: none"> ○ The intravenous (IVIG) and subcutaneous immune globulin (SCIG) <i>Preferred Product Criteria</i> [section of this policy] applies to the state of Arizona ○ Immune globulin is proven for the treatment of: <ul style="list-style-type: none"> § Asthma (severe, persistent, high-dose steroid-dependent) § Autoimmune uveitis § Enteroviral meningoencephalitis § Graves’ ophthalmopathy § Rheumatoid arthritis, severe § Rotaviral enterocolitis ○ Immune globulin is unproven and not medically necessary for the treatment of acute disseminated encephalomyelitis (ADEM) <p>Multiple Sclerosis, Relapsing Forms</p> <ul style="list-style-type: none"> • Revised list of treatments to which the patient must have a history of failure, contraindication, or intolerance; added natalizumab-sztn (Tyruko®) <p>Neuromyelitis Optica</p> <ul style="list-style-type: none"> • Updated list of examples of complement inhibitors; added Ultomiris (ravulizumab) <p>Applicable Codes</p> <ul style="list-style-type: none"> • Added ICD-10 diagnosis codes B34.3, B97.35, D59.11, G04.00, G04.01, O98.711, O98.712, O98.713, O98.719, O98.72, O98.73, T45.AX5A, T45.AX5D, T45.AX5S, Z21, Z92.26, Z94.0, Z94.1, Z94.2, Z94.3, Z94.4, Z94.82, and Z94.83 • Removed ICD-10 diagnosis codes A08.0, A87.0, A88.0, H20.00, H20.011, H20.012, H20.013, H20.019, H20.021, H20.022, H20.023, H20.029, H20.041, H20.042, H20.043, H20.049, J45.51, J45.52, M05.00, M05.011, M05.012, M05.019, M05.021, M05.022, M05.029, M05.031, M05.032, M05.039, M05.041, M05.042, M05.049, M05.051, M05.052, M05.059, M05.061, M05.062, M05.069, M05.071, M05.072, M05.079, M05.09, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.29, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.622, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.7A, M06.1, M08.00, M08.011, M08.012, M08.019, M08.021, M08.022, M08.029, M08.031, M08.032, M08.039, M08.041, M08.042, M08.049, M08.051, M08.052, M08.059, M08.061, M08.062, M08.069, M08.071, M08.072, M08.079, M08.08, M08.09, M08.0A, M08.20, M08.211, M08.212, M08.219, M08.221, M08.222, M08.229, M08.231, M08.232, M08.239, M08.241, M08.242, M08.249, M08.251, M08.252, M08.259, M08.261, M08.262, M08.269, M08.271, M08.272, M08.279, M08.28, M08.29, M08.2A, M08.3, M08.40, M08.411, M08.412, M08.419, M08.421, M08.422, M08.429, M08.431, M08.432, M08.439, M08.441, M08.442, M08.449, M08.451, M08.452, M08.459, M08.461, M08.462, M08.469, M08.471, M08.472, M08.479, M08.48, M08.4A, M08.80, M08.811, M08.812, M08.819, M08.821, M08.822, M08.829, M08.831, M08.832, M08.839, M08.841, M08.842, M08.849, M08.851, M08.852, M08.859, M08.861, M08.862, M08.869, M08.871, M08.872, M08.879, M08.88, M08.89, M08.90, M08.911,

Date	Summary of Changes
	<p>M08.912, M08.919, M08.921, M08.922, M08.929, M08.931, M08.932, M08.939, M08.941, M08.942, M08.949, M08.951, M08.952, M08.959, M08.961, M08.962, M08.969, M08.971, M08.972, M08.979, M08.98, M08.99, and M08.9A</p> <p>Supporting Information</p> <ul style="list-style-type: none"> • Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information • Archived previous policy version CS2025D0035SS

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria , to assist us in administering health benefits. The UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.